Prediagnostic circulating markers of inflammation and risk of prostate cancer

International Journal of Cancer

Volumn 133, Issue 12, 2013, Pages 2961-2967

  Toriola, Adetunji T ^a,b   Laukkanen, Jari A ^c,d   Kurl, Sudhir ^c   Nyyssönen, Kristiina ^c,e   Ronkainen, Kimmo ^c   Kauhanen, Jussi ^c  

^a University School of Medicine   (United States)

^b Washington University in St Louis School of Medicine   (United States)

^c UNIVERSITY OF EASTERN FINLAND   (Finland)

^d LAPLAND CENTRAL HOSPITAL   (Finland)

^e Municipal Authority for Medical and Social Services in Kymenlaakso   (Finland)

Author keywords

C reactive protein; fibrinogen; inflammation; leukocyte count; prostate cancer

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN;

ADULT; ARTICLE; CANCER MORTALITY; CANCER RISK; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FIBRINOGEN BLOOD LEVEL; FINLAND; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN BLOOD LEVEL;

C-REACTIVE PROTEIN; FIBRINOGEN; INFLAMMATION; LEUKOCYTE COUNT; PROSTATE CANCER;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FINLAND; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK;

EID: 84885587482     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28313     Document Type: Article

References (48)

1. Sfanos KS, De Marzo AM,. Prostate cancer and inflammation: the evidence. Histopathology 2012; 60: 199-215.
2. De Marzo AM, Platz EA, Sutcliffe S, et al. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007; 7: 256-69.
3. Hsing AW, Chokkalingam AP,. Prostate cancer epidemiology. Front Biosci 2006; 11: 1388-413.
4. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
5. Sutcliffe S, Platz EA,. Inflammation in the etiology of prostate cancer: an epidemiologic perspective. Urol Oncol 2007; 25: 242-9.
6. Dennis LK, Dawson DV,. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology 2002; 13: 72-9.
7. Kirby RS, Lowe D, Bultitude MI, et al. Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis. Br J Urol 1982; 54: 729-31.
8. Montironi R, Mazzucchelli R, Scarpelli M,. Precancerous lesions and conditions of the prostate: from morphological and biological characterization to chemoprevention. Ann N Y Acad Sci 2002; 963: 169-84.
9. Ruska KM, Sauvageot J, Epstein JI,. Histology and cellular kinetics of prostatic atrophy. Am J Surg Pathol 1998; 22: 1073-7.
10. De Marzo AM, Marchi VL, Epstein JI, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol 1999; 155: 1985-92.
11. Dasgupta K, Di Cesar D, Ghosn J, et al. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006; 12: 130-5.
12. Nelson JE, Harris RE,. Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case-control study. Oncol Rep 2000; 7: 169-70.
13. Roberts RO, Jacobson DJ, Girman CJ, et al. A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc 2002; 77: 219-25.
14. Mahmud SM, Franco EL, Aprikian AG,. Use of nonsteroidal anti-inflammatory drugs and prostate cancer risk: a meta-analysis. Int J Cancer 2010; 127: 1680-91.
15. Heikkila K, Ebrahim S, Lawlor DA,. A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Commun Health 2007; 61: 824-33.
16. Platz EA, De Marzo AM, Erlinger TP, et al. No association between pre-diagnostic plasma C-reactive protein concentration and subsequent prostate cancer. Prostate 2004; 59: 393-400.
17. Stark JR, Li H, Kraft P, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer 2009; 124: 2683-9.
18. Van Hemelrijck M, Jungner I, Walldius G, et al. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. Int J Cancer 2011; 129: 1485-92.
19. Il'yasova D, Colbert LH, Harris TB, et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort. Cancer Epidemiol Biomarkers Pre 2005; 14: 2413-8.
20. Pierce BL, Biggs ML, DeCambre M, et al. C-reactive protein, interleukin-6, and prostate cancer risk in men aged 65 years and older. Cancer Causes Control 2009; 20: 1193-203.
21. Heikkila K, Ebrahim S, Rumley A, et al. Associations of circulating C-reactive protein and interleukin-6 with survival in women with and without cancer: findings from the British Women's Heart and Health Study. Cancer Epidemiol Biomarkers Prev 2007; 16: 1155-9.
22. Toriola AT, Kurl S, Laukanen JA, et al. Alcohol consumption and risk of colorectal cancer: the Findrink study. Eur J Epidemiol 2008; 23: 395-401.
23. Laukkanen JA, Pukkala E, Rauramaa R, et al. Cardiorespiratory fitness, lifestyle factors and cancer risk and mortality in Finnish men. Eur J Cancer 2010; 46: 355-63.
24. Salonen JT,. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988; 20: 46-50.
25. Teppo L, Pukkala E, Lehtonen M,. Data quality and quality control of a population-based cancer registry. Experience in Finland. Acta Oncol 1994; 33: 365-9.
26. Pukkala E,. Finland-cancer registration Cancer atlas of Northern Europeed. Helsinki: Cancer Society of Finland, 2001. 50-1.
27. Rissanen TH, Voutilainen S, Virtanen JK, et al. Low intake of fruits, berries and vegetables is associated with excess mortality in men: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study. J Nutr 2003; 133: 199-204.
28. Lynch JW, Kaplan GA, Cohen RD, et al. Do cardiovascular risk factors explain the relation between socioeconomic status, risk of all-cause mortality, cardiovascular mortality, and acute myocardial infarction? Am J Epidemiol 1996; 144: 934-42.
29. Kauhanen J, Kaplan GA, Goldberg DE, et al. Beer binging and mortality: results from the Kuopio ischaemic heart disease risk factor study, a prospective population based study. Br Med J 1997; 315: 846-51.
30. Sutcliffe S, Giovannucci E, De Marzo AM, et al. Gonorrhea, syphilis, clinical prostatitis, and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15: 2160-6.
31. Scherer PE,. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55: 1537-45.
32. Calle EE, Kaaks R,. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4: 579-91.
33. Kahn SE, Hull RL, Utzschneider KM,. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 2006; 444: 840-6.
34. Margolis KL, Rodabough RJ, Thomson CA, et al. Women's Health Initiative Research G. Prospective study of leukocyte count as a predictor of incident breast, colorectal, endometrial, and lung cancer and mortality in postmenopausal women. Arch Intern Med 2007; 167: 1837-44.
35. Sprague BL, Trentham-Dietz A, Klein BE, et al. Physical activity, white blood cell count, and lung cancer risk in a prospective cohort study. Cancer Epidemiol Biomarkers Prev 2008; 17: 2714-22.
36. Iida M, Ikeda F, Ninomiya T, et al. White blood cell count and risk of gastric cancer incidence in a general Japanese population: The Hisayama Study. Am J Epidemiol 2012; 175: 504-10.
37. Shankar A, Wang JJ, Rochtchina E, et al. Association between circulating white blood cell count and cancer mortality: a population-based cohort study. Arch Intern Med 2006; 166: 188-94.
38. dos Santos Silva I, De Stavola BL, Pizzi C, et al. Circulating levels of coagulation and inflammation markers and cancer risks: individual participant analysis of data from three long-term cohorts. Int J Epidemiol 2010; 39: 699-709.
39. Elkahwaji JE, Hauke RJ, Brawner CM,. Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate. Br J Cancer 2009; 101: 1740-8.
40. Collins MM, Meigs JB, Barry MJ, et al. Prevalence and correlates of prostatitis in the health professionals follow-up study cohort. J Urol 2002; 167: 1363-6.
41. Nickel JC, Downey J, Young I, et al. Asymptomatic inflammation and/or infection in benign prostatic hyperplasia. BJU Int 1999; 84: 976-81.
42. Gupta S, Srivastava M, Ahmad N, et al. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 2000; 42: 73-8.
43. Yoshimura R, Sano H, Masuda C, et al. Expression of cyclooxygenase-2 in prostate carcinoma. Cancer 2000; 89: 589-96.
44. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-7.
45. Ulrich CM, Bigler J, Potter JD,. Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils, and pharmacogenetics. Nat Rev Cancer 2006; 6: 130-40.
46. Veitonmaki T, Tammela TL, Auvinen A, et al. Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer 2013; 49: 938-45.
47. Garcia Rodriguez LA, Gonzalez-Perez A,. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13: 649-53.
48. Pogodin-Hannolainen D, Juusela H, Tammela TLJ, et al. Prostate cancer screening: a survey of attitudes and practices among Finnish physicians in 1999 and 2007. J Med Screen 2011; 18: 46-9.